With a changing of the guard, the Federal Trade Commission (FTC) is undergoing some major restructuring, gearing up to be an aggressive antitrust watchdog. All told, it’s not just Big Tech and pharmaceutical companies that should be on alert.
March was a telling month as to how high a priority antitrust will be for the agency and the Biden administration, generally. In a key move, Acting Chair Rebecca Kelly Slaughter on March 25 announced the creation of a new rulemaking group within the Office of the General Counsel, which will “allow the FTC to take a strategic and harmonized approach to rulemaking across its different authorities and mission areas.”
